Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

A new trial has found that a weight loss drug taken monthly helps people lose 20 percent of their body weight. Weight loss ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Chewy Inc (NYSE:CHWY) shares are trading lower in Monday's after-hours session after the company announces a public offering ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

The S&P 500 advanced 1% on Monday, June 23, 2025, as investors weighed the potential severity and impact of Iran's ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea.

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.